Search results for: C.P. Denton

Items from 1 to 12 out of 12 results

article

The critical need for patient‐reported outcome measures to assess the severity and impact of systemic sclerosis

M. Hughes, C.P. Denton

British Journal of Dermatology > 186 > 1 > 11 - 12

article

The patient knows best: a new self‐reported outcome measure for systemic sclerosis

K.E.N. Clark, C.P. Denton

British Journal of Dermatology > 183 > 4 > 610 - 610

article

Prospective evaluation of treatment response and disease reversibility of paediatric localized scleroderma (morphoea) to steroids and methotrexate using multi‐modal imaging

L. Weibel, M. Theiler, K.J. Howell, C.P. Denton, more

Journal of the European Academy of Dermatology and Venereology > 34 > 7 > 1609 - 1616

Background Paediatric localized scleroderma is a severe inflammatory disorder associated with tissue atrophy, often leading to disability. Assessing disease activity and response to treatment has always been challenging and remains an important difficulty in clinical practice. Objectives To investigate prospectively the efficacy of systemic treatment with corticosteroids and methotrexate in children...

article

European dermatology forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

R. Knobler, P. Moinzadeh, N. Hunzelmann, A. Kreuter, more

Journal of the European Academy of Dermatology and Venereology > 31 > 10 > 1581 - 1594

The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features,...

article

European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

R. Knobler, P. Moinzadeh, N. Hunzelmann, A. Kreuter, more

Journal of the European Academy of Dermatology and Venereology > 31 > 9 > 1401 - 1424

The term ‘sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features,...

article

The molecular pathogenesis of morphoea: from genetics to future treatment targets

A.M. Saracino, C.P. Denton, C.H. Orteu

British Journal of Dermatology > 177 > 1 > 34 - 46

A number of immunoinflammatory and profibrotic mechanisms are recognized in the pathogenesis of broad sclerotic skin processes and, more specifically, morphoea. However, the precise aetiopathogenesis is complex and remains unclear. Morphoea is clinically heterogeneous, with variable anatomical patterning, depth of tissue involvement and sclerotic, inflammatory, atrophic and dyspigmented morphology...

article

The clinical relevance of sexual dysfunction in systemic sclerosis

C. Bruni, J. Raja, C.P. Denton, M. Matucci-Cerinic

Autoimmunity Reviews > 2015 > 14 > 12 > 1111-1115

Systemic sclerosis is a chronic multi-organ autoimmune disease, leading to important clinical and psychological implications. Among organ complications, sexual dysfunction is a major issue for both male and female gender, with high prevalence and great impact on quality of life, although frequently not addressed by both clinicians and patients. While erectile dysfunction is the most common cause of...

article

Dysfunctional Endothelial Progenitor Cells may Contribute to Vasculopathy in Systemic Sclerosis

R.W. Good, S.L. Trinder, C.P. Denton, D.J. Abraham, more

European Journal of Vascular & Endovascular Surgery > 2014 > 47 > 6 > 694

article

Biomarkers for skin involvement and fibrotic activity in scleroderma

P. Moinzadeh, C.P. Denton, D. Abraham, V. Ong, more

Journal of the European Academy of Dermatology and Venereology > 26 > 3 > 267 - 276

Systemic sclerosis (scleroderma, SSc) is characterized as a severe and very heterogeneous disease with a bright variation of skin and organ manifestations in individual patients. The pathogenesis is still not fully elucidated; however, it is known that this disease starts with an initial vascular damage, which then leads to an inflammatory process and finally promotes the development of an accumulation...

article

Systemic sclerosis as a model of chronic rejection in facial composite tissue transplantation

B. Sivakumar, N. Haloob, A. Puri, A. Latif, more

Journal of Plastic, Reconstructive & Aesthetic Surgery > 2010 > 63 > 10 > 1669-1676

Chronic rejection remains a potential significant long-term problem of facial allograft transplantation. Scleroderma parallels chronic rejection in terms of its immunological pathophysiology and its histopathological processes. Through the analysis of facial changes in scleroderma we demonstrate how chronic facial allograft rejection may present and progress.129 consecutive patients with a clinical...

article

The role of radiology in the management of systemic sclerosis

G. Madani, R.D. Katz, J.A. Haddock, C.P. Denton, more

Clinical Radiology > 2008 > 63 > 9 > 959-967

Systemic sclerosis is a multisystem connective tissue disorder. Radiology plays an integral part in its management, guiding the clinician concerning the onset and severity of visceral involvement. After skin involvement, the gastrointestinal tract is the most commonly affected system; contrast radiography and magnetic resonance imaging (MRI) play a role in diagnosis. Non-specific interstitial pneumonia...

article

Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy

C.P. Denton, C.M. Black, J.H. Korn, B. de Crombrugghe

The Lancet > 1996 > 347 > 9013 > 1453-1458

Although there is no cure for systemic sclerosis, the disease is certainly treatable. And the more that is understood of its pathogenesis, the better the prospects for treatment. Excessive collagen deposition in the skin and viscera is responsible for the morbidity and mortality. The immune system plays a critical role in setting up the fibrotic process, but impaired regulation of collagen gene expression...

Filter options

Publication date

Last 3 years (1)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

Keywords

CHRONIC REJECTION (1)
COMPOSITE TISSUE ALLOTRANSPLANTATION (1)
ERECTILE DYSFUNCTION (1)
FACE TRANSPLANTATION (1)
SEXUAL DYSFUNCTION (1)
SYSTEMIC SCLEROSIS (1)

Data set

Wiley (7)
Elsevier (5)

INFONA - science communication portal

Search results for: C.P. Denton

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options